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nhibitory Smads (I-Smads) repress signaling by cytokines
of the transforming growth factor-
 
 
 
 (TGF-
 
 
 
) superfamily.
I-Smads have conserved carboxy-terminal Mad homology
2 (MH2) domains, whereas the amino acid sequences of their
amino-terminal regions (N domains) are highly divergent
from those of other Smads. Of the two different I-Smads in
mammals, Smad7 inhibited signaling by both TGF-
 
 
 
 and
bone morphogenetic proteins (BMPs), whereas Smad6 was
less effective in inhibiting TGF-
 
 
 
 signaling. Analyses using
deletion mutants and chimeras of Smad6 and Smad7 re-
vealed that the MH2 domains were responsible for the
inhibition of both TGF-
 
 
 
 and BMP signaling by I-Smads,
but the isolated MH2 domains of Smad6 and Smad7 were
I
 
less potent than the full-length Smad7 in inhibiting TGF-
 
 
 
signaling. The N domains of I-Smads determined the
subcellular localization of these molecules. Chimeras
containing the N domain of Smad7 interacted with the
TGF-
 
 
 
 type I receptor (T
 
 
 
R-I) more efﬁciently, and were
 
more potent in repressing TGF-
 
 
 
 signaling, than those
containing the N domain of Smad6. The isolated N domain
of Smad7 physically interacted with the MH2 domain of
Smad7, and enhanced the inhibitory activity of the latter
through facilitating interaction with TGF-
 
 
 
 receptors. The
N domain of Smad7 thus plays an important role in the
speciﬁc inhibition of TGF-
 
 
 
 signaling.
 
Introduction
 
Members of the transforming growth factor-
 
 
 
 (TGF-
 
 
 
)*
superfamily are multifunctional cytokines that regulate
growth, differentiation, motility, adhesion, and morphogenesis
of various types of cells (Roberts and Sporn, 1990; Massagué,
1998). The TGF-
 
 
 
 superfamily includes TGF-
 
 
 
s, activins,
bone morphogenetic proteins (BMPs), growth/differentiation
factors, and Müllerian inhibiting substance. Cytokines of
the TGF-
 
 
 
 superfamily bind to two different types of serine/
threonine kinase receptors termed types II and I, and transmit
intracellular signals by Smad proteins (Heldin et al., 1997;
Massagué and Wotton, 2000; Miyazono et al., 2000). Of
the three different subtypes of Smads, receptor-regulated
Smads (R-Smads) are directly phosphorylated by type I
serine/threonine kinase receptors, and form oligomeric
complexes with common mediator Smads (Co-Smads). The
R-Smad–Co-Smad complexes then translocate into the
nucleus, where they regulate the transcription of target
genes.
The third class of Smads comprises the inhibitory Smads
(I-Smads), which include Smad6 and Smad7 in mammals
and Daughters against Decapentaplegic in 
 
Drosophila
 
.
Expression of I-Smads is induced by various stimuli, e.g.,
TGF-
 
 
 
 and BMPs (Miyazono, 2000). Smad2 and Smad3,
activated by TGF-
 
 
 
, and Smad1 and Smad5, activated by
BMPs, bind to the promoter regions and induce the tran-
scription of 
 
Smad7
 
 and 
 
Smad6
 
 genes, respectively (Nagarajan et
al., 1999; Denissova et al., 2000; Ishida et al., 2000). Daughters
against Decapentaplegic is also induced by Decapentaplegic
signaling (Tsuneizumi et al., 1997). Thus, I-Smads act as
components in negative feedback regulation in the Smad
signaling pathways. I-Smads stably bind to activated type I
receptors, and compete with R-Smads for receptor activation
(Hayashi et al., 1997; Imamura et al., 1997; Nakao et al.,
1997; Souchelnytskyi et al., 1998). In addition, Smad7, and
possibly Smad6, recruit E3 ubiquitin ligases Smurf1 and
Smurf2 to type I receptors, leading to ubiquitin-dependent
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degradation of the TGF-
 
 
 
 receptor complexes (Kavsak et al.,
2000; Ebisawa et al., 2001). Smad6 has also been reported
to form a complex with Smad1, and to compete with Smad4
for oligomer formation (Hata et al., 1998). Moreover,
Smad6 has been shown to bind certain transcription factors
and repress transcription in the nucleus (Bai et al., 2000).
R-Smads and Co-Smads have highly conserved amino-
and carboxy-terminal regions termed Mad homology 1
(MH1) and MH2 domains, respectively, that are linked by
linker regions of variable length and sequence. I-Smads have
conserved MH2 domains, but their amino-terminal do-
mains (N domains) are highly divergent from the MH1 do-
mains and linker regions of other Smads. Moreover, amino
acid sequences of the N domains are only partially conserved
between the I-Smads (36.7% between Smad6 and Smad7).
Notably, Smad6 and Smad7 have been identified in 
 
Xeno-
pus
 
, but their N domains are only 51.3 and 67.4% identical
to their mammalian homologues, respectively (Nakayama et
al., 1998a,b).
Although I-Smads inhibit signaling by members of the
TGF-
 
 
 
 superfamily, significant differences have been ob-
served in their biological activities. BMP signaling is antago-
nized by both Smad6 and Smad7 (Hata et al., 1998; Fujii et
al., 1999; Ishisaki et al., 1999), whereas Smad7 is more po-
tent than Smad6 in repressing TGF-
 
 
 
 and activin signaling.
Thus, Smad7 has been reported to antagonize the growth
inhibition, matrix formation, apoptosis induction, and em-
bryonic lung morphogenesis induced by TGF-
 
 
 
 or activin
(Itoh et al., 1998; Ishisaki et al., 1999; Zhao et al., 2000).
Moreover, bleomycin-induced lung fibrosis, which is medi-
ated by endogenous production of TGF-
 
 
 
, is prevented by
the administration of adenovirus containing Smad7, but not
Smad6 (Nakao et al., 1999).
To elucidate the functional differences between Smad7
and Smad6 in the repression of TGF-
 
 
 
 signaling and to de-
termine how Smad7 efficiently inhibits this signaling, we ex-
amined the activities of deletion mutants and chimeras of
Smad6 and Smad7. Our present findings revealed that the
carboxy-terminal MH2 domains of Smad6 and Smad7 are
essential for the inhibition of TGF-
 
 
 
 and BMP signaling,
and the N domain of Smad7 is required for efficient inhibi-
tion of TGF-
 
 
 
 signaling by Smad7. We also found that
the N domains determine the subcellular localization of
I-Smads. Physical interaction of Smad7 with TGF-
 
 
 
 type I
receptor (T
 
 
 
R-I) was found to be one of the most important
mechanisms for inhibiting TGF-
 
 
 
 signaling. Intriguingly,
the isolated N domain of Smad7 physically interacted with
the Smad7 MH2 domain, and enhanced the inhibitory ac-
tivity of the latter through facilitating its interaction with
T
 
 
 
R-I.
 
Results
 
Smad7 is more potent than Smad6 in inhibiting
TGF-
 
 
 
 signaling
 
We examined the inhibition by I-Smads of TGF-
 
 
 
 and
BMP signaling using transcriptional response assays. We
compared the activities of Smad6 and Smad7 using two
different promoter–reporter constructs, p3TP–Lux and
AR3–Luc, which preferentially respond to TGF-
 
 
 
/activin
signaling. Two different types of cells, i.e., R mutant
Mv1Lu mink lung epithelial cells and COS7 cells, were
used for the transcriptional assays. Smad7 potently inhib-
ited the transcriptional activation of p3TP–Lux induced
by a constitutively active form of T
 
 
 
R-I, T
 
 
 
R-I(TD), in
Figure 1. Inhibition of TGF-  and BMP signaling by I-Smads. (A and 
B) Comparison of the inhibitory effects of Smad6 and Smad7 on 
transcription from p3TP–Lux (A) and AR3–Luc (B) induced 
byT R-I(TD). In A–C, R mutant Mv1Lu cells or COS7 cells were 
transfected with the indicated plasmids, and luciferase activities were 
determined as described in the Materials and methods.   and    
are 0.1 and 0.3  g of DNA, respectively, transfected in R mutant or 
COS7 cells. 6 and 7 denote Smad6 and Smad7, respectively. For the 
analysis using AR3–Luc, FAST1/FoxH3 cDNA was cotransfected. (C) 
Comparison of the inhibitory effects of Smad6 and Smad7 on 3GC2–
Lux transcription induced by a BMPR-I, ALK-6(QD). (D) Inhibitory
effects of Smad6 and Smad7 on Tlx2–Lux transcription induced by 
ALK-6(QD) and BMPR-II. P19 embryonal carcinoma cells were 
transfected with the indicated plasmids, and luciferase activities were 
determined as described in the Materials and methods.   and    
are 0.1 and 0.3  g of DNA, respectively, transfected in P19 cells. 
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both R mutant cells and COS7 cells (Fig. 1 A). In con-
trast, Smad6 was less potent than Smad7 in inhibiting the
transcriptional activation induced by T
 
 
 
R-I(TD). Simi-
lar results were obtained using the AR3–Luc promoter–
reporter construct (Fig. 1 B), which contains the pro-
moter region of 
 
Xenopus
 
 
 
Mix.2
 
 and responds to TGF-
 
 
 
/
activin signaling in the presence of a forkhead transcrip-
tion factor, FAST1/FoxH3.
Transcriptional repression by I-Smads was determined
using 3GC2–Lux activated by a constitutively active BMP
type I receptor (BMPR-I), ALK-6(QD). In contrast to
their differential effects on the inhibition of TGF-
 
 
 
 signal-
ing, both Smad6 and Smad7 inhibited BMP signaling in-
duced by ALK-6(QD). Another BMP-responsive luciferase
construct, Tlx2–Lux, was also tested to examine the effects
of I-Smads on BMP signaling. Again, Smad6 and Smad7
were nearly equal in their inhibition of BMP signaling in-
duced by ALK-6(QD) (Fig. 1 D). Thus, Smad7 is more
potent than Smad6 in inhibiting TGF-
 
 
 
 signaling,
whereas Smad6 and Smad7 were functionally equivalent in
inhibiting BMP signaling.
 
The N domain of Smad7 is important for the inhibition 
of TGF-
 
 
 
 signaling
 
We next examined which parts of Smad7 are responsible
for the inhibition of TGF-
 
 
 
 signaling. We prepared dele-
tion mutants of Smad6 and Smad7 (Fig. 2 A). Smad6N
and Smad7N have only the N domains of Smad6 and
Smad7, respectively, whereas Smad6C and Smad7C con-
tain their MH2 domains. We also generated a chimeric
molecule containing the N domain of Smad6 and the
MH2 domain of Smad7 (Smad6/7), and one containing
the Smad7 N domain and the Smad6 MH2 domain
(Smad7/6).
The isolated N domains of Smad6 and Smad7
(Smad6N and Smad7N) were unable to repress TGF-
 
 
 
signaling induced by T
 
 
 
R-I(TD) (Fig. 2 B). In contrast,
the MH2 domains of Smad6 and Smad7 (Smad6C and
Smad7C) repressed the transcriptional activity of T
 
 
 
R-
I(TD) to extents similar to that induced by the full-length
Smad6, but were less potent than the full-length Smad7.
Thus, the MH2 domains of Smad6 and Smad7 are essen-
tial for repression of TGF-
 
 
 
 signaling, but are not suffi-
cient for the efficient transcriptional repression observed
with Smad7.
We also examined the two different Smad6 and Smad7
chimeras, i.e., Smad6/7 and Smad7/6. Smad7/6 was as po-
tent as Smad7, whereas Smad6/7 was functionally similar to
Smad6 in the inhibition of TGF-
 
 
 
 signaling (Fig. 2 B).
Thus, the N domain of Smad7 is important for the efficient
transcriptional repression induced by Smad7.
Inhibition by Smad6 and Smad7 of BMP signaling was
also studied using the 3GC2–Lux promoter–reporter
construct. The N domains of Smad6 and Smad7 were not
effective in inhibiting BMP signaling (Fig. 2 C). Smad6C
and Smad7C were nearly as potent as the full-length
Smad6 and Smad7, suggesting that the MH2 domains
may be sufficient for repression of BMP signaling. This
finding was further confirmed by the observation that the
Smad6 and Smad7 chimeras, Smad6/7 and Smad7/6, po-
tently inhibited the signaling activity of the BMPR-I.
 
Multiple parts of the Smad7 N domain may be 
responsible for specific inhibition of TGF-
 
 
 
 signaling
 
To determine which parts of the N domain of Smad7 are es-
sential for efficient inhibition of TGF-
 
 
 
 signaling, we con-
structed Smad7 chimeras in which the amino-terminal re-
gions were replaced by the corresponding regions of Smad6
(Fig. 3 A). In the N domain of Smad7, the most amino-ter-
minal region (amino acids 1–17) and the region adjacent to
the MH2 domain (amino acids 192–213) are highly con-
Figure 2. Inhibition of TGF-  or BMP signaling by Smad6 and 
Smad7 mutants. (A) Structures of Smad6 and Smad7 and their
deletion mutants and chimeras. The amino acid numbers of Smad6 
and Smad7 are indicated. (B) Inhibitory effects of I-Smads and their 
deletion mutants and chimeras on p3TP–Lux transcription induced 
by T R-I(TD). In B and C, R mutant Mv1Lu cells were transfected 
with the indicated plasmids, and luciferase activities were determined. 
  and    are 0.1 and 0.3  g of DNA, respectively, transfected in R 
mutant cells. (C) Inhibitory effects of I-Smads and their deletion
mutants and chimeras on 3GC2–Lux transcription induced by
ALK-6(QD). 
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served between Smad6 and Smad7, whereas the other re-
gions are less conserved. Functional analyses of the Smad7
chimeras by p3TP–Lux and AR3–Luc assays revealed that
depending on the length of the N domain of Smad7 re-
placed by that of Smad6, the inhibitory activity of Smad7
became gradually less potent (Fig. 3, B and C). A significant
difference in the inhibition of TGF-
 
 
 
 signaling was ob-
served in AR3–Luc when amino acids 32–90 of Smad7 were
replaced by the corresponding region of Smad6. The amino
acid sequence of this Smad7 region is divergent from that of
Smad6. These findings suggest that multiple parts of the
Smad7 N domain may contribute to specific inhibition of
TGF-
 
 
 
 signaling, and that the region containing amino ac-
ids 32–90 is one of the most important regions in the
Smad7 N domain for repressing TGF-
 
 
 
 signaling.
 
N domains determine subcellular 
localization of I-Smads
 
Smad7 has been reported to be located in the nuclei of
COS7 cells (Itoh et al., 1998). Moreover, Smad7 is exported
to the cytoplasm upon stimulation by TGF-
 
 
 
 (Itoh et al.,
1998), as well as by E3 ubiquitin ligases Smurf1 and Smurf2
(Kavsak et al., 2000; Ebisawa et al., 2001). We examined
which parts of I-Smads determine their subcellular localiza-
tion. As reported previously (Itoh et al., 1998; Kavsak et al.,
2000; Ebisawa et al., 2001), Smad7 was predominantly lo-
cated in the nuclei of transfected COS7 cells, whereas
Smad6 was observed in the nuclei as well as in the cytoplasm
(Fig. 4 A). The cytoplasmic staining of Smad6 was observed
as a dotted pattern. In contrast, Smad6C and Smad7C were
detected in the nucleus (unpublished data; see Fig. 8, C and
D). The subcellular localization of the Smad7 chimeras de-
pended on their amino-terminal regions. Thus, S6(31/32)S7
and S6(171/91)S7 were detected in the nucleus, similar to
Smad7, whereas S6(225/158)S7 and S6(279/211)S7 were
detected as cytoplasmic dotted patterns. These results indi-
cate that the region containing amino acids 91–157 of
Smad7 plays an important role in determining the subcellu-
lar localization of Smad7 in COS7 cells.
We also examined the subcellular localization of Smad6,
Smad7, and their chimeras in other cell types. In contrast to
the findings obtained with COS7 cells, Smad7 was predom-
inantly located in the cytoplasm, whereas Smad6 was de-
tected in both the cytoplasm and the nucleus in HepG2 cells
(Fig. 4 B). Subcellular localization of the Smad6 and Smad7
chimeras in HepG2 cells also revealed that the localization
of I-Smads depended on the amino-terminal region of
Smad6 and Smad7, although the chimeras exhibited compli-
cated localization patterns. S6(31/32)S7 and S6(225/158)S7
were detected in the cytoplasm, similar to the full-length
Smad7, whereas S6(171/91)S7 and S6(279/211)S7 were in
both the nucleus and the cytoplasm. Similar results were ob-
tained when R mutant Mv1Lu cells were used (unpublished
data). Thus, the localization of Smad7 in HepG2 and R mu-
tant Mv1Lu cells is different from that in COS7 cells, and
multiple parts of the Smad7 N domain appear to determine
the subcellular localization of Smad7 in these cells. How-
ever, subcellular localization may not primarily determine
the potency of Smad7 in inhibiting TGF-
 
 
 
 signaling, be-
cause the changes in subcellular localization observed with
the Smad6 and Smad7 chimeras did not necessarily correlate
with the inhibitory activity of Smad7 on TGF-
 
 
 
 signaling.
 
Smurf1 induces nuclear export of both 
Smad6 and Smad7
 
Smurf1 induces the nuclear export of Smad7 through an in-
teraction with the Smad7 PY motif, and induces ubiquitin-
dependent degradation of Smad7 and T
 
 
 
R-I. The nuclear
export of Smad7 is not dependent on the enzymatic activity
of Smurf1, as an enzymatically inactive form of Smurf1,
Smurf1(CA), induces the nuclear export of Smad7 (Ebi-
sawa et al., 2001). We examined whether Smurf1 regulates
Figure 3. Multiple regions in the Smad7 
N domain are important for efficient
inhibition of TGF-  signaling. (A) 
Structures of the Smad6 and Smad7
chimeras are shown. The amino acid 
numbers of Smad6 and Smad7 are
indicated. (B and C) Inhibition of TGF-  
signaling by the Smad6 and Smad7
chimeras. Effects of the chimeras on 
p3TP–Lux (B) and AR3–Luc (C)
transcription induced by T R-I(TD) were 
examined.   and    are 0.1 and 0.3 
 g of DNA, respectively, transfected in 
R mutant cells. FAST1/FoxH3 cDNA was 
cotransfected in C. 
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the subcellular localization of Smad6, Smad7, and their
mutants. Smurf1(CA) induced cytoplasmic localization of
Smad6 and Smad7 in both COS7 cells and HepG2 cells
(Fig. 5, A and B). However, Smad6C and Smad7C, which
lack the PY motif, were not exported to the cytoplasm by
Smurf1(CA) (Fig. 5 C).
Functional importance of the I-Smad PY motif was exam-
ined by a p3TP–Lux assay. S7
 
 
 
191, which lacks the amino-
terminal 191 amino acids of Smad7, is less potent than the
full-length Smad7 in inhibiting TGF-
 
  signaling. Further
deletion including the PY motif of Smad7 (S7 210) re-
sulted in a dramatic decrease in the inhibition of TGF-  sig-
naling (Fig. 5 D). In contrast, S6(279/211)S7 was not so
weak as S7 210 in inhibiting TGF-  signaling (Fig. 3 B),
probably because S6(279/211)S7 contains the PY motif of
Smad6. These findings suggest that in agreement with a pre-
vious report (Ebisawa et al., 2001), the PY motif is required
for the nuclear export of I-Smads and the degradation of
T R-I, and the absence of the PY motif leads to a decrease
in the inhibition of TGF-  signaling by I-Smads. However,
because Smurf1 can interact with Smad6 and Smad7, the in-
teraction of I-Smads with Smurf1 may not be responsible for
the differential activity of Smad6 and Smad7.
Repression of Smad2 phosphorylation by I-Smads 
correlates with their inhibition of transcription 
induced by T R-I(TD)
The abilities of the deletion mutants and chimeras of Smad6
and Smad7 to inhibit Smad2 phosphorylation were exam-
ined in transfected COS7 cells. Consistent with the results
obtained with transcriptional activation assays (Fig. 2 B),
phosphorylation of Smad2 was abolished by Smad7 and
Smad7/6 (Fig. 6). Smad6, Smad6/7, Smad6C, and Smad7C
were less potent in inhibiting Smad2 phosphorylation. As
expected, the N domains of Smad6 and Smad7 did not af-
fect the phosphorylation of Smad2. I-Smads have been re-
ported to regulate TGF- /BMP signaling through various
mechanisms, i.e., competition with R-Smads for receptor ac-
tivation, ubiquitin-dependent degradation of receptors by
Smurfs, prevention of complex formation between R-Smads
and Co-Smads, and transcriptional repression in the nu-
cleus. Because the levels of Smad2 phosphorylation corre-
late with the repression of p3TP–Lux transcription by the
I-Smad mutants, Smad7 might regulate TGF-  signal-
ing mainly at the receptor level through competition with
R-Smads for receptor activation and degradation by Smurfs.
The N domain of Smad7 determines the affinity 
of Smad7 for T R-I
Because the interaction between I-Smads and T R-I appears
to be one of the most critical mechanisms in the efficient in-
hibition of TGF-  signaling, we explored the physical inter-
action of I-Smads and their mutants with T R-I. We first
examined the interaction between I-Smad constructs with
the T R-I and T R-II receptor complex cross-linked with
125I–TGF- 1. Fig. 7 A demonstrates that the T R-II–T R-
I complex was efficiently coimmunoprecipitated by full-
length Smad7 and Smad7/6. In contrast, Smad6C and
Smad7C weakly interacted with the TGF-  receptor com-
plexes, and the full-length Smad6 and Smad6/7 did so only
Figure 4. Subcellular localization of I-Smads. Subcellular localization of Smad6, Smad7, and their chimeras was determined in transfected 
COS7 (A) or HepG2 cells (B). FLAG-tagged I-Smads were transfected in cells and the subcellular localization of I-Smads was demonstrated by 
FITC. Nuclear staining was performed by 4,6-diamidino-2-phenylindole (PI).1022 The Journal of Cell Biology | Volume 155, Number 6, 2001
very weakly. The receptor complexes were not coimmuno-
precipitated by the N domains of Smad6 or Smad7. This
finding is consistent with those obtained with the transcrip-
tional assays (Fig. 2 B), indicating that the direct association
of I-Smads with TGF-  receptor complexes is an important
mechanism in the inhibition of TGF-  signaling.
As T R-I acts as a downstream component of T R-II, we
next investigated whether I-Smads and their mutants physi-
cally interact with the constitutively active form of T R-I.
Immunoprecipitation of the I-Smad constructs followed
by immunoblotting of T R-I(TD) revealed that the full-
length Smad7 and Smad7/6 bound to T R-I(TD) strongly,
whereas Smad6 and Smad6/7 did so only weakly (Fig. 7 B).
Of the chimeras between Smad6 and Smad7, S6(31/32)S7
bound to T R-I(TD) strongly. However, the other chime-
ras bound to T R-I(TD) less strongly, depending on the
lengths of the N domain of Smad7, and their binding affin-
ity correlated with their potency in inhibiting TGF-  signal-
ing, analyzed by transcriptional assays (Fig. 3). When the in-
teraction of the I-Smad chimeras with a constitutively active
BMPR-I, ALK-6(QD), was examined by immunoprecipita-
tion followed by immunoblotting, we observed no differ-
ences in affinity with ALK-6(QD) among the I-Smad chi-
meras (unpublished data).
The N domain of Smad7 potentiates the inhibitory 
activity of its MH2 domain through physical interaction
To elucidate the mechanism by which the N domain
of Smad7 represses TGF-  signaling, we cotransfected
Smad7N with Smad7C, and examined the inhibition of
TGF-  signaling by p3TP–Lux assays. Although Smad7N
alone was unable to inhibit TGF-  signaling, cotransfection
of Smad7N with Smad7C led to potent inhibition (Fig. 8
A). In contrast, cotransfection of Smad6N with Smad6C
(Fig. 8 A) or Smad7C (unpublished data) did not signifi-
cantly induce further inhibition of TGF-  signaling com-
pared with transfection of Smad6C alone. When Smad7N
was cotransfected with the MH2 domain of Smad3, it did
not modulate the transcriptional activity of the latter (un-
published data). These results indicate that the N domain of
Smad7 potentiates the inhibitory activity of its MH2 do-
main in trans.
We next examined whether Smad7N can physically inter-
act with the MH2 domains of Smads. As shown in Fig. 8 B,
Smad7N was able to interact with Smad7C. Smad7N also
interacted with Smad6C (unpublished data), but failed to
associate with the MH2 domains of Smad3 or Smad1 (Fig.
8 B). We also tested the interaction of Smad6N with the
MH2 domains of I-Smads. Smad6N weakly interacted with
Smad6C, but not with Smad7C (unpublished data).
We examined the localization of Smad7C in the presence
and absence of Smad7N in HepG2 and COS7 cells. In
HepG2 cells, Smad7 was detected in the cytoplasm (Fig. 4
B), whereas Smad7C was detected in the nucleus (Fig. 8 C).
However, when Smad7N was cotransfected, Smad7C was
observed in the cytoplasm (Fig. 8 C). Moreover, Smad7C
and Smad7N were colocalized in HepG2 cells, consistent
with the observation that they physically interact with each
other. In COS7 cells, Smad7 and Smad7C were detected in
the nucleus (Figs. 8 D and 4 A). Co-transfection of either
Smurf1(CA) or Smad7N did not induce the nuclear export
of Smad7C. However, Smad7C was detected in the cyto-
plasm in the presence of both Smad7N and Smurf1(CA)
(Fig. 8 D).
We then studied the interaction of Smad7C with the
TGF-  receptors in the presence and absence of Smad7N by
affinity cross-linking, followed by immunoprecipitation of
Figure 5. Smurf1 induces nuclear export of Smad6 and Smad7.
(A–C) The nuclear export of Smad6, Smad7, and their deletion
mutants (Smad6C and Smad7C) induced by Smurf1(CA) was examined 
in COS7 (A) or HepG2 cells (B and C) as in Fig. 4. (D) The effects of 
Smad7 amino-terminal deletion mutants on p3TP–Lux transcription 
induced by T R-I(TD) were examined.   and    are 0.3 and 1.0 
 g of DNA, respectively, transfected in R mutant cells. PPPY
represents the PY motif.Role of the N domain of Smad7 | Hanyu et al. 1023
FLAG–Smads. Smad7C weakly interacted with the TGF- 
receptor complex, whereas Smad7N alone failed to do so, as
shown in Fig. 7 A. However, strong interaction between
Smad7C and the TGF-  receptor complex was detected in
the presence of Smad7N (Fig. 8 E). Smurf1 facilitates the in-
teraction of Smad7 with TGF-  receptors by targeting
Smad7 to the plasma membrane (unpublished data). In the
presence of Smurf1, Smad7C efficiently interacted with
TGF-  receptors when cotransfected with Smad7N (Fig. 8
E). By immunoprecipitation of Smad7N, the TGF-  recep-
tor complex was weakly coimmunoprecipitated in the pres-
ence of Smurf1 and Smad7C, suggesting that Smad7N in-
teracts with these receptors indirectly through Smad7C.
These findings suggest that Smad7N physically interacts
with Smad7C, leading to an increase in the affinity between
Smad7C and the TGF-  receptors.
Discussion
The N domain of Smad7 is important for repressing 
TGF-  signaling
We have shown in the present study that Smad7 is more po-
tent than Smad6 in inhibiting TGF-  signaling, whereas
Smad6 and Smad7 are functionally similar in repressing
Figure 6. Repression of Smad2 phosphorylation by
I-Smads, their deletion mutants, and chimeras. COS7 
cells were transfected with the indicated plasmids, and 
phosphorylation of Smad2 was determined by FLAG 
immunoprecipitation of Smad2, followed by
phosphoserine immunoblotting (top). Levels of expression 
for each protein were determined by immunoblotting 
using FLAG, HA, or Myc antibodies (lower).   and    
are 0.1 and 0.3  g of DNA, respectively, transfected in 
COS7 cells.
Figure 7. Physical interaction of Smads with TGF-  receptors. 
(A) Affinity cross-linking using 
125I–TGF- 1 followed by immuno-
precipitation by anti-FLAG antibody was performed using COS7 
cells transfected with the indicated plasmids (top). Levels of
expression of I-Smads and their mutants and chimeras were
examined by immunoblotting using anti-FLAG antibody (bottom). 
(B) Interaction of I-Smads with T R-I(TD) was examined by FLAG 
immunoprecipitation of I-Smads, followed by HA-immunoblotting 
of T R-I(TD) using transfected COS7 cells (top). The Smad6 and Smad7 chimeras shown in Fig. 3 A were used. 6(32), S6(31/32)S7; 
6(91), S6(171/91)S7; 6(158), S6(225/158); 6(211), S6(279/211)S7. Note that HA-tagged T R-I(TD) was comigrated with IgG. Lower 
panels demonstrate the levels of expression of I-Smads (middle) and T R-I(TD) (bottom).1024 The Journal of Cell Biology | Volume 155, Number 6, 2001
Figure 8. Physical interaction of Smad7N leads to nuclear export and 
enhancement of the inhibitory activity of Smad7C. (A) Enhancement 
of the inhibitory activity of Smad7C by Smad7N. Effects of Smad6N 
and Smad7N were examined in the presence of their MH2 domains 
(Smad6C and Smad7C) by a p3TP–Lux transcription assay induced by 
T R-I(TD).   and    are 0.1 and 0.3  g of DNA, respectively,
transfected in R mutant cells. (B) Physical interaction between Smad7N 
and the MH2 domains of Smad7 (7C), Smad3 (3C), and Smad1 (1C). 
Interaction of Smad7N with the full-length Smad7 (7) was also tested. 
Interaction was examined by FLAG immunoprecipitation of
FLAG–Smads, followed by Myc immunoblotting of Smad7N using 
transfected COS7 cells (top). Expression levels of transfected proteins 
were determined and are shown in the lower two panels. (C and D) 
Subcellular localization of Smad7C in the presence and absence of 
Smad7N was examined in transfected HepG2 (C) or COS7 cells (D) 
using confocal laser scanning microscopy. FLAG–Smad7C was stained 
by anti-FLAG antibody in the absence and presence of Smad7N and 
Smurf1(CA), and its subcellular localization was demonstrated by FITC. 
In HepG2 cells, 6Myc–Smad7N was stained by rhodamine 
isothiocyanate (RITC; C, bottom). (E) Affinity cross-linking of 
125I–TGF-
 1 was performed using transfected COS7 cells followed by FLAG
immunoprecipitation of FLAG–I-Smads (upper). The lower two panels 
demonstrate the levels of expression of transfected proteins.Role of the N domain of Smad7 | Hanyu et al. 1025
BMP signaling. Analyses by p3TP–Lux and AR3–Luc assays
revealed that the N domain of Smad7 plays an important role
in efficient inhibition of TGF-  signaling. Although multiple
regions of the N domain of Smad7 appeared to contribute to
the repression of TGF-  signaling, the transcriptional assay
using AR3–Luc and the interaction of the I-Smad chimeras
with T R-I(TD) suggested that the region containing amino
acids 31–90 of Smad7 is one of the most important regions
for the efficient inhibition of TGF-  signaling.
The N domains of Smad6 and Smad7 have thus far been
poorly investigated. The amino acid sequences of the N do-
mains are not highly conserved between Smad6 and Smad7
(36.7%). However, certain regions, e.g., the most amino-
terminal part (amino acids 1–17) and a region adjacent to
the MH2 domain (amino acids 192–213), are relatively well
conserved. The region adjacent to the MH2 domain con-
tains a PY motif that is important for interacting with the E3
ubiquitin-ligases Smurf1 and Smurf2 (Kavsak et al., 2000;
Ebisawa et al., 2001).
The present findings obtained using Smad chimeras ap-
pear to be inconsistent with those described in a recent study
using Xenopus assays (Nakayama et al., 2001). However, the
Smad6/7 chimera used by Nakayama et al. (2001) contains
the amino acids 1–154 of Smad6 and 182–382 of Smad7,
which is similar to the S6(225/158)S7 chimera in the
present study. It will be interesting to examine whether re-
placing the rest of the N domain of Smad7 with that of
Smad6 results in an alteration of the inhibitory activity of
Smad6/7 chimeras in Xenopus assays.
Subcellular localization of I-Smads
Localization in cells is differentially regulated between
Smad6 and Smad7. Smad7 has been reported to be located
in the nucleus of transfected COS7 cells (Itoh et al., 1998),
whereas Smad6 is distributed in both the nucleus and the
cytoplasm. Intriguingly, we found that Smad7 was predomi-
nantly located in the cytoplasm in HepG2 cells and R mu-
tant Mv1Lu cells, although the reason for the difference in
localization of Smad7 between these cell types is unknown.
T R-I(TD) has been shown to induce nuclear export of
Smad7 (Itoh et al., 1998), but not of Smad6; however, in
the present study we were unable to clearly induce the nu-
clear export of Smad7 by T R-I(TD) (unpublished data).
We also found that Smurf1 induces nuclear export of
Smad6 and Smad7, whereas Smad6C and Smad7C, which
lack the ability to interact with Smurf1, were not exported
to the cytoplasm even in the presence of Smurf1. These
findings suggest that the weak inhibitory activity of Smad6C
and Smad7C may be, at least in part, due to their lack of in-
teraction with Smurfs. However, as the PY motif is present
in both Smad6 and Smad7, and Smurf1 can interact equally
well with both of them (Ebisawa et al., 2001), this region
may not solely account for the functional difference between
these I-Smads.
Analyses using Smad6 and Smad7 chimeras revealed that
various regions of Smad7 play roles in the subcellular local-
ization of Smad7. Intriguingly, Smad7 is differentially lo-
cated in either the cytoplasm or the nucleus depending on
cell type. It is possible that proteins expressed in only certain
types of cells may specifically interact with Smad7 through
various regions in the N domain, and thereby induce its nu-
clear export or import. Although subcellular localization dif-
fers between S6(171/91)S7 and S6(225/158)S7 in COS7
cells and between S6(171/91)S7, S6(225/158)S7, and
S6(279/211)S7 in HepG2 and R mutant Mv1Lu cells, inhi-
bition of TGF-  signaling differed only slightly between
these chimeras. Thus, subcellular localization of I-Smads
might not be the major determinant of the differential ef-
fects on the inhibition of TGF-  signaling, and other mech-
anisms may also play important roles in their inhibitory sig-
naling.
Interaction of I-Smads with T R-I
As levels of Smad2 phosphorylation correlated very well
with the inhibitory activity of the I-Smad chimeras, mecha-
nisms mediated upstream of Smad2 phosphorylation, i.e.,
interaction of I-Smads with type I receptors and ubiquitin-
dependent degradation of these receptors, may play impor-
tant roles in the specific inhibition of TGF-  signaling. By
replacing parts of the N domain of Smad7 with the corre-
sponding regions of Smad6, we found that depending on
the lengths of the N domain of Smad7, the I-Smad chimeras
interacted with T R-I less efficiently, and their inhibitory
activities became less potent. Intriguingly, a significant de-
crease in the interaction between the I-Smad chimeras and
T R-I(TD) was observed when amino acids 31–90 of
Smad7 were replaced, suggesting that this region may be one
of the important regions for efficient inhibition of TGF- 
signaling by Smad7.
The L45 loop of type I serine/threonine kinase receptors
directly interacts with the L3 loop in the MH2 domains of
R-Smads, and determines the specificity of inhibitory signals
(Chen et al., 1998; Lo et al., 1998). The L45 loops of T R-I
and activin type IB receptor/ALK-4 interact with and acti-
vate Smad2 and Smad3, whereas the BMPR-I L45 loops
bind to Smad1 and Smad5. The L45 loop of type I receptors
may also interact with the L3 loops of I-Smads. However,
the amino acid sequences of the L3 loops of I-Smads are di-
vergent from those of R-Smads. Thus, the L3 loops of
Smad6 and Smad7 may have low affinity interactions with
T R-I, and the N domain of Smad7, but not Smad6, is re-
quired for efficient interaction. In contrast, interaction of
ALK-6 with the MH2 domains of Smad6 and Smad7 might
occur with high affinity. Thus, the N domain of Smad6 or
Smad7 does not appear to be required for the inhibition of
BMP signaling. It will be important to determine the modes
of interaction between type I receptors and I-Smads by
three-dimensional analysis.
Physical interaction between the 
N and MH2 domains of Smad7
Interestingly, Smad7N alone did not inhibit TGF-  signal-
ing, but Smad7N and Smad7C together potently repressed
it, as reported by Nakayama et al. (2001). We showed in the
present study that Smad7N physically interacts with its
MH2 domain, and suggested that its ability to do so is im-
portant for its inhibition of TGF-  signaling. Smad7N in-
duced the nuclear export of Smad7C in HepG2 cells. In
COS7 cells, Smad7N required Smurf1 for the nuclear ex-
port of Smad7C. Finally, we demonstrated that Smad7N1026 The Journal of Cell Biology | Volume 155, Number 6, 2001
enhances the interaction of Smad7C with the TGF-  recep-
tor complex. Thus, Smad7N has the ability to physically in-
teract with Smad7C, which might result in a conformational
change of the MH2 domain and enhancement of its affinity
for the receptor complex.
The amino-terminal MH1 domains of R-Smads have been
shown to physically interact with their MH2 domains (Hata et
al., 1997). However, the MH1 domains of R-Smads repress the
activity of their MH2 domains through physical interaction,
and this interaction is released upon receptor activation and
phosphorylation of R-Smads. In contrast, the N domain of
Smad7 physically interacts with the MH2 domain, resulting in
enhancement of the inhibitory activity of Smad7 through facili-
tation of the interaction with TGF-  receptors (Fig. 9). Our
present study also revealed that Smad7N specifically interacts
with the MH2 domains of I-Smads, but not with those of
R-Smads. Thus, the present findings suggest a new mode of ac-
tion for the Smad7 N domain in supporting the inhibitory ac-
tivity of the MH2 domain in TGF-  signaling.
Materials and methods
Construction of plasmids
The original constructions of constitutively active forms of T R-I and ALK-6
(T R-I[TD] and ALK-6[QD], respectively), T R-II, BMPR-II, Smad1,
Smad2, Smad3, Smad6, Smad7, Smurf1(CA), and FAST1/FoxH3 cDNAs
were created as previously described (Imamura et al., 1997; Kawabata et
al., 1998; Hanai et al., 1999; Ebisawa et al., 2001). FLAG–pcDNA3,
6Myc–pcDNA3, and pcDNA3–HA were created as described previously
(Inoue et al., 1998; Kawabata et al., 1998). Deletion mutants and chimeras
of Smad6 and Smad7 were prepared by a PCR-based approach. To obtain
efficient levels of protein expression, some constructs, including all the
FLAG-tagged Smad constructs, were subcloned into pcDEF3 (Goldman et
al., 1996). Expression levels of transfected Smad proteins were similar
when they were examined by immunoblotting. All of the PCR products
were sequenced before use.
Cell culture and cDNA transfection
R mutant Mv1Lu mink lung epithelial cells (gift of J. Massagué, Memorial
Sloan-Kettering Cancer Center, New York, NY, and M. Laiho, Haartman
Institute, University of Helsinki, Finland), COS7 cells, HepG2 cells
(American Type Culture Collection accession number HB-8065), and
P19 embryonal carcinoma cells (gift of T. Momoi, National Institute of
Neuroscience, Kodaira, Tokyo, Japan) were cultured in DME containing
10% fetal bovine serum and antibiotics. Cells were transiently trans-
fected using FuGENE6 (Roche Diagnostics) following the manufacturer’s
recommendations.
Luciferase assay
R mutant mink lung epithelial cells, COS7 cells, or P19 embryonal carci-
noma cells were transiently transfected with an appropriate combination
of p3TP–lux (Cárcamo et al., 1994), AR3–Luc (Hayashi et al., 1997),
3GC2–Lux (Ishida et al., 2000), or Tlx2–Lux (Tang et al., 1998) promoter–
reporter constructs, expression plasmids, and pcDNA3. Total amounts of
transfected DNAs were the same in each experiment, and values were nor-
malized using Renilla luciferase activity. All the Smad constructs used in
luciferase assays were subcloned in pcDEF3, and their protein expression
levels were verified by immunoblotting before use or in parallel with lu-
ciferase assays.
Immunoprecipitation and immunoblotting
COS7 cells, transfected with expression constructs, were solubilized in a
buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet
P-40, 1% aprotinin, and 1 mM phenylmethyl sulfonyl fluoride. The cell ly-
sates were precipitated by centrifugation and the supernatants were incu-
bated with anti-FLAG M2 (Eastman Kodak Co.) antibody for 1 h, followed
by incubation with protein A– or G–Sepharose beads. The beads were
washed four times with the buffer used for cell solubilization. The immune
complexes were then eluted by boiling for 3 min in SDS sample buffer
(100 mM Tris-HCl, pH 8.8, 0.01% bromophenol blue, 36% glycerol, 4%
SDS, 10 mM DTT) and applied to SDS-PAGE. Aliquots of the cell lysates
were directly subjected to SDS-PAGE without immunoprecipitation. Pro-
teins were electrotransferred to ProBlott membranes (Applied Biosystems)
and immunoblotted with anti-HA 3F10 (Boehringer), anti-phosphoserine
(Zymed Laboratories), anti-FLAG M2, or anti-myc 9E10 (PharMingen) anti-
bodies and detected using an ECL detection system (Amersham Pharmacia
Biotech). For reblotting, the membranes were stripped in accordance with
the manufacturer’s protocol.
Affinity cross-linking analysis
Recombinant TGF- 1 (R&D Systems) was iodinated using the chloramine
T method (Frolik et al., 1984). COS7 cells were transfected with expression
vectors, and affinity cross-linked using 
125I–TGF- 1. Subsequent immuno-
precipitation and analysis by SDS-PAGE were performed as previously de-
scribed (Imamura et al., 1997).
Immunofluorescence labeling
Immunohistochemical staining of Smad6 and Smad7 was performed using
transfected COS7, HepG2, or R mutant cells. Eight-well Lab-Tek chamber
slides (Nalge Nunc International) were treated with 0.03 mg/ml Cellmatrix
type IV (Nitta Gelatin Co., Ltd.) at 37 C for 30 min. Cells were seeded in
the chambers, transfected with indicated cDNAs, and incubated for an ad-
ditional 24 h. Cells were then fixed and treated with mouse anti-FLAG an-
tibody and biotinylated horse anti–mouse IgG (affinity purified IgG [H L];
Vector Laboratories), followed by incubation with FITC-labeled Avidin
DCS (Vector Laboratories). For double staining of FLAG- and 6Myc-tagged
Smads, 6Myc–Smads were stained using rabbit anti-Myc antibody (gift of
C.-H. Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden), fol-
lowed by incubation with rhodamine isothiocyanate–labeled goat anti–
rabbit IgG (Cappel). The nuclei were stained by 4,6-diamidino-2-phenylin-
dole. Intracellular localization was determined by confocal laser scanning
microscopy.
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